Literature DB >> 1867354

Histologic evolution of basal cell carcinoma recurrence.

A Y Dixon1, S H Lee, D H McGregor.   

Abstract

The biological behavior and appropriate therapy of recurrent basal cell carcinoma (BCCA) is controversial, with some studies suggesting that this tumor becomes more aggressive with each recurrence, and other studies indicating that the majority are aggressive from the onset. The authors studied the histologic evolution of BCCA by comparing 29 original tumors with their subsequent recurrences to determine if there were any predictable histologic changes. There were borderline statistically significant changes only in degree of fibrosis, prominence of nucleoli, and mitotic frequency. There were no statistically significant changes in any of the other parameters, including those that were shown previously to be predictive of recurrence or aggressive behavior. The results of this study clearly indicate that the majority of recurrent BCCAs are aggressive from the onset, and that in many cases this can be predicted from the histomorphology of the original tumor.

Entities:  

Mesh:

Year:  1991        PMID: 1867354     DOI: 10.1097/00000372-199106000-00005

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  3 in total

1.  Value of p53 protein in biological behavior of basal cell carcinoma and in normal epithelia adjacent to carcinomas.

Authors:  N C Demirkan ; N Colakoglu ; E Düzcan
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Correlation of Global MicroRNA Expression With Basal Cell Carcinoma Subtype.

Authors:  Christopher Heffelfinger; Zhengqing Ouyang; Anna Engberg; David J Leffell; Allison M Hanlon; Patricia B Gordon; Wei Zheng; Hongyu Zhao; Michael P Snyder; Allen E Bale
Journal:  G3 (Bethesda)       Date:  2012-02-01       Impact factor: 3.154

3.  Chronicle of a pigmented superficial Basal cell carcinoma.

Authors:  Marie Caucanas; Claudine Piérard-Franchimont; Gérald E Piérard
Journal:  Case Rep Dermatol Med       Date:  2012-07-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.